User profiles for SHEELA RAO
Sheela RaoRoyal Marsden Hospital Verified email at rmh.nhs.uk Cited by 9488 |
[HTML][HTML] Capecitabine and oxaliplatin for advanced esophagogastric cancer
D Cunningham, N Starling, S Rao… - … England Journal of …, 2008 - Mass Medical Soc
Background We evaluated capecitabine (an oral fluoropyrimidine) and oxaliplatin (a platinum
compound) as alternatives to infused fluorouracil and cisplatin, respectively, for untreated …
compound) as alternatives to infused fluorouracil and cisplatin, respectively, for untreated …
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
…, C Ragulan, I Spiteri, SY Moorcraft, I Chau, S Rao… - Science, 2018 - science.org
Patient-derived organoids (PDOs) have recently emerged as robust preclinical models;
however, their potential to predict clinical outcomes in patients has remained unclear. We report …
however, their potential to predict clinical outcomes in patients has remained unclear. We report …
Efficacy of reduced-intensity chemotherapy with oxaliplatin and capecitabine on quality of life and cancer control among older and frail patients with advanced …
Importance Older and/or frail patients are underrepresented in landmark cancer trials. Tailored
research is needed to address this evidence gap. Objective The GO2 randomized clinical …
research is needed to address this evidence gap. Objective The GO2 randomized clinical …
Longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C phase II colorectal cancer clinical trial
…, I Chau, N Tunariu, G Mentrasti, F Trevisani, S Rao… - Cancer discovery, 2018 - AACR
Sequential profiling of plasma cell-free DNA (cfDNA) holds immense promise for early detection
of patient progression. However, how to exploit the predictive power of cfDNA as a liquid …
of patient progression. However, how to exploit the predictive power of cfDNA as a liquid …
[HTML][HTML] Patients' willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey
…, D Cunningham, I Chau, N Starling, D Watkins, S Rao - Trials, 2016 - Springer
Background Recruitment to clinical trials can be challenging and slower than anticipated.
This prospective patient survey aimed to investigate the proportion of patients approached …
This prospective patient survey aimed to investigate the proportion of patients approached …
[PDF][PDF] Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a …
N Starling, S Rao, D Cunningham, T Iveson… - Journal of clinical …, 2009 - Citeseer
… Collection and assembly of data: Naureen Starling, Sheela Rao, … Final approval of
manuscript: Naureen Starling, Sheela Rao, David Cunningham, Timothy Iveson, Marianne …
manuscript: Naureen Starling, Sheela Rao, David Cunningham, Timothy Iveson, Marianne …
[PDF][PDF] Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancer
Despite biomarker stratification, the anti-EGFR antibody cetuximab is only effective against
a subgroup of colorectal cancers (CRCs). This genomic and transcriptomic analysis of the …
a subgroup of colorectal cancers (CRCs). This genomic and transcriptomic analysis of the …
[HTML][HTML] Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative
…, R McWilliams, S Leyvraz, S Rao… - European journal of …, 2015 - Elsevier
Background The past three decades have seen rapid improvements in the diagnosis and
treatment of most cancers and the most important contributor has been research. Progress in …
treatment of most cancers and the most important contributor has been research. Progress in …
[HTML][HTML] International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer …
S Rao, F Sclafani, C Eng, RA Adams… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
… Collection and assembly of data: Sheela Rao, Francesco Sclafani, Annette Bryant Data
analysis and interpretation: Sheela Rao, Francesco Sclafani, Cathy Eng, Richard A. Adams …
analysis and interpretation: Sheela Rao, Francesco Sclafani, Cathy Eng, Richard A. Adams …
[HTML][HTML] Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or …
…, G Spain, LJ Barber, N Matthews, S Rao… - … for immunotherapy of …, 2019 - Springer
Background Patient derived organoids (PDOs) can be established from colorectal cancers (CRCs)
as in vitro models to interrogate cancer biology and its clinical relevance. We applied …
as in vitro models to interrogate cancer biology and its clinical relevance. We applied …